natgillin/translations-raw huggingface dataset:
(2) An element isolated from the human body or otherwise produced by means of a technical process, including the sequence or partial sequence of a gene, may constitute a patentable invention, even if the structure of that element is identical to that of a natural element.
(2) Sestavni del, ki je izoliran iz človeškega telesa ali je pridobljen kako drugače s tehničnim postopkom, vključno z zaporedjem ali delnim zaporedjem gena, je lahko izum, ki ga je mogoče patentirati, tudi če je zgradba tega sestavnega dela enaka zgradbi naravnega sestavnega dela.
(3) The industrial application of a sequence or a partial sequence of a gene must be disclosed in the patent application.
(3) Industrijska uporabljivost zaporedja ali delnega zaporedja gena mora biti razkrita v patentni prijavi.
Filing of the European patent application
Vložitev evropske patentne prijave
(1) European patent applications may be filed in writing with the authorities referred to in Article 75 either directly or by post.
(1) Evropske patentne prijave se lahko vložijo pisno neposredno ali po pošti pri organih iz 75. člena.
The President of the European Patent Office may permit European patent applications to be filed by other means of communication and lay down conditions governing their use.
Predsednik Evropskega patentnega urada lahko dovoli, da se evropske patentne prijave vložijo tudi po drugih komunikacijskih sredstvih, in določi pogoje njihove uporabe.
He may, in particular, require that within such period as the European Patent Office shall specify written confirmation be supplied reproducing the contents of applications so filed and complying with the requirements of these Implementing Regulations.
Zlasti lahko zahteva, da se v roku, ki ga določi Evropski patentni urad, predloži pisna potrditev, v kateri so ponovljene vsebine tako vloženih prijav in ki izpolnjuje pogoje tega pravilnika o izvajanju.
(2) The authority with which the European patent application is filed shall mark the documents making up the application with the date of their receipt.
(2) Organ, pri katerem je vložena evropska patentna prijava, označi na dokumentih, ki sestavljajo prijavo, datum njihovega prejema.
It shall issue without delay a receipt to the applicant which shall include at least the application number, the nature and number of the documents and the date of their receipt.
Prijavitelju takoj izda potrdilo o prejemu, ki vsebuje vsaj številko prijave, vrsto in število dokumentov ter datum njihovega prejema.
(3) If the European patent application is filed with an authority mentioned in Article 75, paragraph 1(b), it shall without delay inform the European Patent Office of receipt of the documents making up the application.
(3) Če je evropska patentna prijava vložena pri organu, omenjenem v pododstavku (b) prvega odstavka 75. člena, ta takoj obvesti Evropski patentni urad o prejemu dokumentov, ki sestavljajo prijavo.
It shall inform the European Patent Office of the nature and date of receipt of the documents, the application number and any priority date claimed.
Evropskemu patentnemu uradu sporoči vrsto in datum prejema dokumentov, številko prijave in vsak zahtevani prednostni datum.
(4) When the European Patent Office has received a European patent application which has been forwarded by a central industrial property office of a Contracting State, it shall inform the applicant accordingly, indicating the date of its receipt at the European Patent Office.
(4) Če je Evropski patentni urad prejel evropsko patentno prijavo od osrednjega urada za industrijsko lastnino države pogodbenice, to sporoči prijavitelju in pri tem navede datum, ko jo je prejel.
Provisions for European divisional applications
Določbe za izločene evropske prijave
(1) The applicant may file a divisional application relating to any pending earlier European patent application.
(1) Prijavitelj lahko vloži izločeno prijavo, ki se nanaša na katero koli še nerešeno prvotno evropsko patentno prijavo.
(2) The filing fee and search fee shall be payable in respect of a European divisional application within one month after the filing thereof.
(2) Prijavna pristojbina in pristojbina za poizvedbo se plačata za izločeno evropsko prijavo v enem mesecu po njeni vložitvi.
The designation fees shall be payable within six months of the date on which the European Patent Bulletin mentions the publication of the European search report drawn up in respect of the European divisional application.
Pristojbine za imenovanje se lahko plačajo v šestih mesecih od datuma, ko je v Evropskem patentnem biltenu omenjena objava evropskega poročila o poizvedbi, sestavljenega za izločeno evropsko prijavo.
Provisions governing the application
Določbe, ki urejajo prijavo
Request for grant
Zahteva za podelitev
(1) The request for the grant of a European patent shall be filed on a form drawn up by the European Patent Office.
(1) Zahteva za podelitev evropskega patenta se vloži na obrazcu, ki ga sestavi Evropski patentni urad.
Printed forms shall be made available to applicants free of charge by the authorities referred to in Article 75, paragraph 1.
Organi iz prvega odstavka 75. člena dajo prijaviteljem brezplačno na razpolago tiskane obrazce.
(2) The request shall contain:
(2) Zahteva vsebuje:
(a) a petition for the grant of a European patent;
(a) zahtevek za podelitev evropskega patenta;
(b) the title of the invention, which shall clearly and concisely state the technical designation of the invention and shall exclude all fancy names;
(b) naziv izuma, v katerem je jasno in zgoščeno predstavljena tehnična označitev izuma in ne vsebuje nobenih domišljijskih imen;
(c) the name, address and nationality of the applicant and the State in which his residence or principal place of business is located.
(c) ime, naslov in državljanstvo prijavitelja ter državo, v kateri ima stalno prebivališče ali sedež podjetja.
Names of natural persons shall be indicated by the person&apos;s family name and given name(s), the family name being indicated before the given name(s).
Za fizične osebe se navedeta priimek in ime, pri čemer mora biti priimek naveden pred imenom.
Names of legal entities, as well as companies considered to be legal entities by reason of the legislation to which they are subject, shall be indicated by their official designations.
Za pravne osebe ali družbe, ki so po pravu, ki velja zanje, obravnavane kot pravne osebe, se navede njihovo uradno ime.
Addresses shall be indicated in such a way as to satisfy the customary requirements for prompt postal delivery at the indicated address.
Naslovi se navedejo tako, da so izpolnjene običajne zahteve za hitro poštno dostavo na navedeni naslov.
They shall in any case comprise all the relevant administrative units, including the house number, if any.
V vsakem primeru morajo naslovi vsebovati vse bistvene podatke, vključno s hišno številko, če obstaja.
It is recommended that the telegraphic and telex address and telephone number be indicated;
Priporoča se tudi navedba telegrafskega naslova ter številke teleksa in telefona;
(d) if the applicant has appointed a representative, his name and the address of his place of business under the conditions contained in sub-paragraph (c);
(d) če je prijavitelj imenoval zastopnika, njegovo ime in naslov njegovega sedeža dejavnosti po pogojih iz pododstavka (c);
(e) where appropriate, indication that the application constitutes a European divisional application and the number of the earlier European patent application;
(e) kadar je primerno, navedbo, da gre za izločeno evropsko prijavo, in številko prejšnje evropske patentne prijave;
(f) in cases covered by Article 61, paragraph 1(b), the number of the original European patent application;
(f) v primerih iz pododstavka (b) prvega odstavka 61. člena številko prvotne evropske patentne prijave;
(g) where applicable, a declaration claiming the priority of an earlier application and indicating the date on which and the country in or for which the earlier application was filed;
(g) kadar je primerno, izjavo, s katero se zahteva prednost prejšnje prijave, z navedbo datuma, ko je bila prejšnja prijava vložena, in države, v kateri ali za katero je bila vložena;
(h) designation of the Contracting State or States in which protection of the invention is desired;
(h) imenovanje države pogodbenice ali držav, v katerih se želi zavarovati izum;
(i) the signature of the applicant or his representative;
(i) podpis prijavitelja ali njegovega zastopnika;
(j) a list of the documents accompanying the request.
(j) seznam dokumentov, priloženih k zahtevi.
This list shall also indicate the number of sheets of the description, claims, drawings and abstract filed with the request;
V tem seznamu se navede tudi število listov opisa, patentnih zahtevkov, skic in povzetka, ki se vložijo skupaj z zahtevo;
(k) the designation of the inventor where the applicant is the inventor.
(k) imenovanje izumitelja, če je prijavitelj izumitelj.
(3) If there is more than one applicant, the request shall preferably contain the appointment of one applicant or representative as common representative.
(3) Če je prijaviteljev več, naj bo v zahtevi po možnosti imenovan en prijavitelj ali en zastopnik kot skupni zastopnik.
(1) The description shall: (a) specify the technical field to which the invention relates;
(1) Opis: (a) natančno določa tehnično področje, na katero se nanaša izum;
(b) indicate the background art which, as far as known to the applicant, can be regarded as useful for understanding the invention, for drawing up the European search report and for the examination, and, preferably, cite the documents reflecting such art;
(b) navaja dotedanje stanje tehnike, ki je, če je prijavitelju znano, lahko koristno za razumevanje izuma, sestavitev evropskega poročila o poizvedbi in za preizkus, ter po možnosti dobesedno navaja dokumente, iz katerih je tako stanje tehnike razvidno;
(c) disclose the invention, as claimed, in such terms that the technical problem (even if not expressly stated as such) and its solution can be understood, and state any advantageous effects of the invention with reference to the background art;
(c) razkriva izum, kot je naveden v patentnem zahtevku, s takimi izrazi, da je mogoče razumeti tehnični problem (tudi če ni izrecno tako imenovan) in njegovo rešitev, ter navaja vse prednostne učinke izuma glede na dotedanje stanje tehnike;
(d) briefly describe the figures in the drawings, if any;
(d) na kratko opisuje morebitne slike iz skic;
(e) describe in detail at least one way of carrying out the invention claimed using examples where appropriate and referring to the drawings, if any;
(e) podrobno opisuje vsaj en način izvedbe izuma, za katerega se zahteva varstvo, s tem da se uporabijo primeri, kjer je ustrezno, in sklicevanje na morebitne skice;
(f) indicate explicitly, when it is not obvious from the description or nature of the invention, the way in which the invention is capable of exploitation in industry.
(f) izrecno navaja način, na katerega je mogoče izum industrijsko izkoriščati, če to ni očitno iz opisa ali narave izuma.
(2) The description shall be presented in the manner and order specified in paragraph 1, unless because of the nature of the invention, a different manner or a different order would afford a better understanding and a more economic presentation.
(2) Opis se izdela na način in po vrstnem redu, ki sta določena v prvem odstavku, razen če zaradi narave izuma drug način ali drug vrstni red ne bi omogočila boljšega razumevanja in smotrnejše predstavitve.
Requirements of European patent applications relating to nucleotide and amino acid sequences
Zahteve za evropske patentne prijave v zvezi z zaporedji nukleotidov in aminokislin
(1) If nucleotide or amino acid sequences are disclosed in the European patent application the description shall contain a sequence listing conforming to the rules laid down by the President of the European Patent Office for the standardised representation of nucleotide and amino acid sequences.
(1) Če so v evropski patentni prijavi razkrita zaporedja nukleotidov ali aminokislin, vsebuje opis prikaz zaporedij, ki je v skladu s predpisi, ki jih je določil predsednik Evropskega patentnega urada za standardno predstavitev zaporedij nukleotidov in aminokislin.
(2) The President of the European Patent Office may require that, in addition to the written application documents, a sequence listing in accordance with paragraph 1 be submitted on a data carrier prescribed by him accompanied by a statement that the information recorded on the data carrier is identical to the written sequence listing.
(2) Predsednik Evropskega patentnega urada lahko zahteva, da se poleg pisnih dokumentov prijave predloži tudi prikaz zaporedij, sestavljen v skladu s prvim odstavkom, na nosilcu podatkov, ki ga predpiše, in da se predloži izjava, da so podatki z nosilca podatkov enaki pisnemu prikazu zaporedij.
(3) If a sequence listing is filed or corrected after the date of filing, the applicant shall submit a statement that the sequence listing so filed or corrected does not include matter which goes beyond the content of the application as filed.
(3) Če se prikaz zaporedij vloži ali popravi po datumu vložitve prijave, mora prijavitelj predložiti izjavo, da tako vloženi ali popravljeni prikaz zaporedij ne vključuje ničesar, kar bi presegalo vsebino prijave, kot je bila vložena.
(4) A sequence listing filed after the date of filing shall not form part of the description.
(4) Prikaz zaporedij, ki je vložen po datumu vložitve prijave, ni del opisa.
Deposit of biological material
Deponiranje biološkega materiala
(1) If an invention involves the use of or concerns biological material which is not available to the public and which cannot be described in the European patent application in such a manner as to enable the invention to be carried out by a person skilled in the art, the invention shall only be regarded as being disclosed as prescribed in Article 83 if:
(1) Če izum vključuje uporabo biološkega materiala ali zadeva biološki material, ki ni dostopen javnosti in ga v evropski patentni prijavi ni mogoče opisati na način, da bi strokovnjak lahko izvedel izum, velja ta za razkritega, kot predpisuje 83. člen, samo:
(a) a sample of the biological material has been deposited with a recognised depositary institution not later than the date of filing of the application;
(a) če je bil vzorec biološkega materiala deponiran pri priznani depozitni ustanovi najkasneje do datuma vložitve prijave;
(b) the application as filed gives such relevant information as is available to the applicant on the characteristics of the biological material;
(b) če prijava, kot je bila vložena, vsebuje vse bistvene podatke o značilnostih biološkega materiala, ki so dostopni prijavitelju;
(c) the depositary institution and the accession number of the deposited biological material are stated in the application, and
(c) če sta v prijavi navedeni depozitna ustanova in številka deponiranega biološkega materiala in
(d) where the biological material has been deposited by a person other than the applicant, the name and address of the depositor are stated in the application and a document is submitted satisfying the European Patent Office that the latter has authorised the applicant to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with this Rule.
(d) kadar je biološki material deponirala oseba, ki ni prijavitelj, če sta v prijavi navedena ime in naslov deponenta in je Evropskemu patentnemu uradu predložen dokument, ki dokazuje, da je deponent pooblastil prijavitelja, da se v prijavi lahko sklicuje na deponirani biološki material, in da je dal absolutno in nepreklicno soglasje, da je deponirani biološki material lahko na razpolago javnosti v skladu s tem pravilom.
(2) The information referred to in paragraph 1(c) and, where applicable, (d) may be submitted
(2) Podatki iz pododstavka (c) prvega odstavka in, kadar je primerno, iz pododstavka (d) prvega odstavka se lahko predložijo:
(a) within a period of sixteen months after the date of filing of the application or, if priority is claimed, after the priority date, this time limit being deemed to have been met if the information is communicated before completion of the technical preparations for publication of the European patent application;
(a) v šestnajstih mesecih po datumu vložitve prijave ali po prednostnem datumu, če se zahteva prednost, pri čemer se šteje, da je bil ta rok upoštevan, če so podatki sporočeni pred zaključkom tehničnih priprav za objavo evropske patentne prijave;
(b) up to the date of submission of a request for early publication of the application;
(b) do datuma predložitve zahteve za predčasno objavo prijave;
(c) within one month after the European Patent Office has communicated to the applicant that a right to inspect the files pursuant to Article 128, paragraph 2, exists.
(c) v enem mesecu od dneva, ko je Evropski patentni urad sporočil prijavitelju, da ima pravico do vpogleda v dokumentacijo na podlagi drugega odstavka 128. člena.
The ruling period shall be the one which is the first to expire.
Odločilni rok je tisti, ki prvi poteče.
The communication of this information shall be considered as constituting the unreserved and irrevocable consent of the applicant to the deposited biological material being made available to the public in accordance with this Rule.
Sporočitev teh podatkov velja kot absolutno in nepreklicno soglasje prijavitelja, da se da deponirani biološki material na razpolago javnosti v skladu s tem pravilom.
(3) The deposited biological material shall be available upon request to any person from the date of publication of the European patent application and to any person having the right to inspect the files pursuant to Article 128, paragraph 2, prior to that date.
(3) Od datuma objave evropske patentne prijave je deponirani biološki material na zahtevo dostopen vsakomur, pred tem datumom pa tistemu, ki ima na podlagi drugega odstavka 128. člena pravico do vpogleda v dokumentacijo.
Subject to paragraph 4, such availability shall be effected by the issue of a sample of the biological material to the person making the request (hereinafter referred to as “the requester“).
Ob upoštevanju četrtega odstavka se dostop omogoči tako, da se vložniku zahteve izda vzorec biološkega materiala.
Said issue shall be made only if the requester has undertaken vis-à-vis the applicant for or proprietor of the patent not to make the biological material or any biological material derived therefrom available to any third party and to use that material for experimental purposes only, until such time as the patent application is refused or withdrawn or deemed to be withdrawn, or before the expiry of the patent in the designated State in which it last expires, unless the applicant for or proprietor of the patent expressly waives such an undertaking.
Vzorec se izda samo, če je vložnik zahteve glede na prijavitelja ali imetnika patenta prevzel obveznost, da biološkega materiala ali iz njega pridobljenega biološkega materiala ne bo dal na razpolago tretji osebi in da ga bo uporabljal zgolj za raziskovalne namene, dokler patentna prijava ni zavrnjena ali umaknjena ali se ne šteje za umaknjeno ali preden je patent prenehal veljati v tistih imenovanih državah, v katerih najkasneje preneha, razen če se prijavitelj ali imetnik patenta izrecno ne odreče takemu prevzemu obveznosti.
The undertaking to use the biological material for experimental purposes only shall not apply in so far as the requester is using that material under a compulsory licence.
Določba o prevzemu obveznosti, da bo biološki material uporabljal samo v raziskovalne namene, ne velja, če vložnik zahteve uporablja ta material na podlagi prisilne licence.
The term “compulsory licence“ shall be construed as including ex officio licences and the right to use patented inventions in the public interest.
Za prisilne licence se štejejo tudi uradne licence in pravica do uporabe patentiranih izumov zaradi javnega interesa.
(4) Until completion of the technical preparations for publication of the application, the applicant may inform the European Patent Office that
(4) Do zaključka tehničnih priprav za objavo prijave lahko prijavitelj sporoči Evropskemu patentnemu uradu, da bo
(a) until the publication of the mention of the grant of the European patent or, where applicable,
(a) do objave omembe o podelitvi evropskega patenta ali, kadar je primerno,
(b) for twenty years from the date of filing if the application has been refused or withdrawn or deemed to be withdrawn, the availability referred to in paragraph 3 shall be effected only by the issue of a sample to an expert nominated by the requester.
(b) dvajset let od datuma vložitve prijave, če je bila ta zavrnjena ali umaknjena ali se šteje za umaknjeno, dostop iz tretjega odstavka omogočen le z izdajo vzorca izvedencu, ki ga imenuje vložnik zahteve.
(5) The following may be nominated as an expert:
(5) Kot izvedenec se lahko imenuje:
(a) any natural person provided that the requester furnishes evidence, when filing the request, that the nomination has the approval of the applicant;
(a) vsaka fizična oseba, če vložnik zahteve ob vložitvi zahteve predloži dokaz, da se prijavitelj strinja z imenovanjem;
(b) any natural person recognised as an expert by the President of the European Patent Office.
(b) vsaka fizična oseba, ki jo predsednik Evropskega patentnega urada prizna kot izvedenca.
The nomination shall be accompanied by a declaration from the expert vis-à-vis the applicant in which he enters into the undertaking given pursuant to paragraph 3 until either the date on which the patent expires in all the designated States or, where the application has been refused, withdrawn or deemed to be withdrawn, until the date referred to in paragraph 4(b), the requester being regarded as a third party.
Skupaj z imenovanjem se predloži tudi izjava izvedenca, da prevzema obveznosti do prijavitelja po tretjem odstavku do datuma, ko varstvo patenta preneha v vseh imenovanih državah, če pa je bila prijava zavrnjena, umaknjena ali se šteje za umaknjeno, do datuma iz pododstavka (b) četrtega odstavka, s tem da se vložnik zahteve šteje za tretjo osebo.
(6) For the purposes of paragraph 3, derived biological material shall mean any material which still exhibits those characteristics of the deposited material which are essential to carrying out the invention.
(6) Za namene tretjega odstavka pridobljeni biološki material pomeni vsak material, ki še kaže tiste značilnosti deponiranega materiala, ki so bistvene za izvedbo izuma.
The undertaking referred to in paragraph 3 shall not impede any deposit of derived biological material necessary for the purpose of patent procedure.
Obveze iz tretjega odstavka niso ovira za deponiranje pridobljenega biološkega materiala, potrebnega za patentni postopek.
(7) The request provided for in paragraph 3 shall be submitted to the European Patent Office on a form recognised by that Office.
(7) Zahteva iz tretjega odstavka se predloži Evropskemu patentnemu uradu na obrazcu, ki ga ta priznava.
The European Patent Office shall certify on the form that a European patent application referring to the deposit of the biological material has been filed, and that the requester or the expert nominated by him is entitled to the issue of a sample of that material.
Evropski patentni urad na obrazcu potrdi, da je bila vložena evropska patentna prijava, ki se nanaša na deponiranje biološkega materiala, in da ima vložnik zahteve ali izvedenec, ki ga je ta imenoval, pravico do izdaje vzorca tega materiala.
After grant of the European patent, the request shall also be submitted to the European Patent Office.
Zahteva se predloži Evropskemu patentnemu uradu tudi po podelitvi evropskega patenta.
(8) The European Patent Office shall transmit a copy of the request, with the certification provided for in paragraph 7, to the depositary institution as well as to the applicant for or the proprietor of the patent.
(8) Evropski patentni urad pošlje kopijo zahteve s potrdilom, predvidenim v sedmem odstavku, depozitni ustanovi in prijavitelju ali imetniku patenta.